Edwards Lifesciences (EW) Cash from Investing Activities (2009 - 2026)

Edwards Lifesciences has reported Cash from Investing Activities for 18 years, with the latest figure at -$92.8 million in Q1 2026.

• For the quarter ending Q1 2026, Cash from Investing Activities fell 208.79% year-over-year to -$92.8 million; the trailing twelve-month figure through Mar 2026 stood at -$891.0 million (down 138.16% YoY), and the FY2025 full-year result was -$712.9 million, down 130.82% from the prior year.
• Cash from Investing Activities for Q1 2026 stood at -$92.8 million, up from -$198.3 million in the prior quarter.
• The five-year high for Cash from Investing Activities was $2.7 billion in Q3 2024, with the low at -$576.7 million in Q4 2024.
• Average Cash from Investing Activities over 5 years is $113.7 million, with a median of $63.1 million recorded in 2024.
• Peak annual rise in Cash from Investing Activities reached 12520.0% in 2024, while the deepest fall reached 4190.07% in 2024.
• Tracing EW's Cash from Investing Activities over 5 years: stood at $94.7 million in 2022, then slumped by 85.11% to $14.1 million in 2023, then plunged by 4190.07% to -$576.7 million in 2024, then soared by 65.61% to -$198.3 million in 2025, then soared by 53.2% to -$92.8 million in 2026.
• The last three Cash from Investing Activities figures came in at -$92.8 million (Q1 2026), -$198.3 million (Q4 2025), and -$427.8 million (Q3 2025), per Business Quant data.

Peer Comparison